Author: acn

MIAMI, FL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy.Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationwide fiber, mobile edge computing, and next-generation network architectures.Prior to Verizon, Mr. Vestberg spent nearly three decades at Ericsson, including almost seven years as its Chief Executive Officer, where he helped build and operate global infrastructure facilitating approximately 35% of worldwide mobile traffic.Mr. Vestberg's appointment comes at a time when AI adoption is increasingly constrained, not by software or silicon, but by power availability, cooling capacity, and deployment speed. Digipower X is working on addressing this challenge through the deployment of the AI-Ready Modular Solution (ARMS) platform, designed to deliver Tier-3 modular AI data centers within approximately 180 days, supported by a vertically integrated power strategy and a growing portfolio of large-scale energy assets."Hans Vestberg built and scaled the physical infrastructure that helped enable the fiber, mobile, and 5G revolutions," said Michel Amar, Chairman and Chief Executive Officer of Digipower X. "He understands what most of the market overlooks: AI's bottleneck isn't algorithms or chips, it's power, cooling, and deployment speed. Hans knows how to execute infrastructure transformation at a national and global scale, and we expect his guidance will be invaluable as we expand our modular AI data center footprint.""I've spent over 30 years building the networks that move data," said Mr. Vestberg. "The next decade is about building the infrastructure that processes it. Digipower X is more than just a data center company. It controls its power, is developing the ability to deploy Tier-3 infrastructure in the near term, and is building a modular platform to address the exact constraints holding back large-scale AI deployment. Its focus on power availability and deployment speed first, real estate second, is exactly the right approach."Infrastructure Experience Aligned with AI ScaleDuring his tenure at Ericsson (2010-2016), Mr. Vestberg led more than 115,000 employees worldwide and positioned the company at the forefront of next-generation wireless technologies. At Verizon (2018-2025), he reshaped the organization around a network-first strategy, oversaw major investments in spectrum and fiber, and advanced distributed edge-compute capabilities to enable data-intensive and latency-sensitive applications.Mr. Vestberg insightfully noted at Davos 2024 that "one of the most important infrastructures of this century is digital infrastructure," and that AI workloads will increasingly migrate from centralized hyperscale facilities toward distributed locations supporting real-time inference and enterprise demand.Mr. Vestberg currently serves as a board member of BlackRock and Verizon.Addressing the Power and Deployment Constraint in AI InfrastructureDigipower X operates a combined-cycle power plant and three additional operating sites, with more than 200 megawatts of power currently online. The Company has secured development capacity to support AI infrastructure expansion over the next three years, with the ability to develop up to an additional 1.5 gigawatts of power capacity, including at major sites in North Carolina and West Virginia.In West Virginia, Digipower X has entered into a letter of intent relating to a 1.3-gigawatt power plant, which is being evaluated as a long-term site for AI data center and advanced computing infrastructure deployment."Hans recognizes that national AI competitiveness depends on solving power availability and deployment speed," said Gerard Rotonda, Board Member of Digipower X and former CFO of Deutsche Bank Wealth & Asset Management Americas. "His experience aligns directly with Digipower X's mission to deliver infrastructure at the scale and speed this market now requires."Vestberg's Strategic FocusIn his advisory role, Mr. Vestberg will work closely with Digipower X's executive team on:AI infrastructure deployment strategy and scaling frameworks;Distributed and edge-compute architectures for inference-driven workloads;Strategic partnerships with hyperscalers, enterprises, and infrastructure stakeholders;Power optimization and energy-efficient data center design;Tier-3 redundancy and mission-critical reliability standards; andInternational expansion strategy and site prioritization.About Digipower XDigipower X is an innovative energy infrastructure company that develops Tier III-certified modular AI data centers and drives the expansion of sustainable energy assets.For further information, please contact:Michel Amar, Chief Executive OfficerDigipower X Inc.www.digipowerx.comInvestor RelationsT: 888-474-9222Email: IR@digihostpower.comCautionary StatementTrading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking StatementsExcept for the statements of historical fact, this news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. Forward-looking information in this news release includes information about the Company's expectations concerning the potential contributions by our new advisor to the Company's strategic efforts, the potential further improvements to profitability and efficiency across the Company's operations, including, as a result of the Company's expansion efforts, potential for the Company's long-term growth and clean energy strategy, and the business goals and objectives of the Company. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to: delivery of equipment and implementation of systems may not occur on the timelines anticipated by the Company or at all; future capital needs and uncertainty of additional financing; share dilution resulting from equity issuances; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; statements regarding the timing, scale and expansion of AI and high-performance computing infrastructure; changes in demand for AI and high-performance computing; future data center capacity may not be realized at the level anticipated by the Company, or at all; development of additional facilities and installation of infrastructure to expand operations may not be completed on the timelines anticipated by the Company, or at all; ability to access additional power from the local power grid; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company's operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company's filings at www.sedarplus.ca and www.SEC.gov/EDGAR. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about, among other things, profitable use of the Company's assets going forward; the demand for data center capacity for AI and high-performance computing; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainties therein. The Company undertakes no obligation to revise or update any forward-looking information other than as required by applicable law.SOURCE: Digi Power X Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEEDHAM, MA, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.Under the agreement, research will be conducted at the University of Minnesota under the direction of Dr. Kevin Mayo, a recognized expert in biomolecular structure and nuclear magnetic resonance spectroscopy The collaboration is designed to further characterize carbohydrate-binding interactions that may play a role in future therapeutic and diagnostic applications.“This collaboration with the University of Minnesota represents an important step in strengthening the scientific foundation behind our carbohydrate-based technology platform,” said David Platt, CEO of Bioxytran. “By leveraging the University’s deep expertise in structural biology and advanced nuclear magnetic resonance spectroscopy, we aim to generate high-quality data that supports the continued evolution of our research and development pipeline.”Research FocusThe sponsored research program will explore how specific polysaccharides and related carbohydrate structures interact with target molecules relevant to biological systems. Using state-of-the-art nuclear magnetic resonance methodologies, the research team will analyze binding interactions, structural conformations, and affinity characteristics of select carbohydrate compounds. The work is expected to build on Bioxytran’s existing research into carbohydrate-based materials and their potential applications across biomedical and life-science domains. Findings from the study may help guide future development strategies and inform additional preclinical research initiatives.Academic–Industry CollaborationThe agreement reflects a shared commitment to advancing scientific knowledge through collaboration between academia and industry. The University of Minnesota will carry out the research in accordance with its established academic standards, ensuring scientific rigor, transparency, and adherence to institutional research policies.This type of partnership exemplifies how academic research institutions and innovative companies can work together to address complex scientific questions,” said Dr. Kevin Mayo, Principal Investigator and Professor at the University of Minnesota. “Our goal is to apply advanced analytical tools to generate insights that are both scientifically meaningful and relevant to real-world applications.”Timeline and StructureThe research term is expected to run through early 2027, with defined milestones, periodic progress reviews, and structured reporting. Bioxytran will provide funding to support research personnel, nuclear magnetic resonance facility access, and associated laboratory resources required to execute the program. In accordance with standard sponsored research practices, the University of Minnesota will retain ownership of any intellectual property generated through the research, while Bioxytran will receive broad rights to use the resulting research data for internal research and development purposes.Strategic SignificanceFor Bioxytran, the collaboration supports a broader strategy focused on strengthening its scientific validation, expanding academic partnerships, and advancing next-generation carbohydrate technologies. The company believes that well-characterized molecular interactions are a critical step toward unlocking new therapeutic pathways and accelerating innovation.The University of Minnesota continues to be recognized globally for its leadership in biomedical research and technology transfer, making it an ideal partner for companies seeking to bridge fundamental science and commercial development.About the University of MinnesotaThe University of Minnesota is one of the nation’s leading public research universities, known for its commitment to discovery, innovation, and the translation of research into real-world impact. Through industry partnerships and sponsored research programs, the University fosters collaboration that advances science and benefits society.About Bioxytran, Inc.Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation. Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.Company Contact:Bioxytran, Inc.75 Second Avenue, Needham, MA 02494Phone: 617‑454‑1199Email: info@Bioxytraninc.comWeb: www.Bioxytraninc.comForward-Looking StatementsThis press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年1月30日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司 （「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市，詳見康哲藥業日期為2025年4月22日發佈的公告）已於2026年1月30日獲得中國國家藥品監督管理局（NMPA）批准磷酸蘆可替尼乳膏（白癜風適應症）（「產品」）新藥上市許可申請（NDA）。產品用於治療12歲及以上兒童和成人患者伴面部受累的非節段型白癜風，是中國批准的首款且唯一用於白癜風治療的靶向藥，滿足巨大未被滿足的臨床需求。磷酸蘆可替尼乳膏是經美國食品和藥物管理局（FDA）及歐洲藥品管理局（EMA）批准的首款也是唯一一款用於非節段型白癜風複色的藥物[1,2]，在產品正式獲得NDA批准之前，康哲藥業受益於國家賦予海南自由貿易港及樂城先行區（「樂城先行區」）「先行先試」政策、「港澳藥械通」政策、北京市及天津自貿試驗區的臨床急需進口藥品政策，已啟動磷酸蘆可替尼乳膏的試點應用。目前博鰲超級醫院已為超7,000名非節段型白癜風患者開具磷酸蘆可替尼乳膏處方，且廣州、深圳、東莞、佛山、中山、珠海、江門、惠州、北京及天津共二十餘家醫院已提供該藥品處方服務，體現了其臨床價值。產品在境外臨床研究與中國真實世界研究中均展現出積極結果：其在境外開展的兩項相同設計的III期雙盲、隨機、安慰劑對照研究（TRuE-V1和TRuE-V2）中，產品治療24周後達到主要療效指標面部白癜風面積評分指數改善至少75%（F-VASI 75）的患者比例均為29.9%，顯著高於安慰劑組的7.5%和12.9%，持續使用至52周，複色效果持續[3]。根據樂城先行區藥品真實世界數據應用試點項目有關規定，磷酸蘆可替尼乳膏在中國開展真實世界研究，療效積極，與境外關鍵臨床研究結果一致。境內外臨床研究中所有的次要療效指標均顯示出與主要療效指標一致的獲益趨勢，且白癜風治療效果隨療程延長持續改善。同時，根據樂城先行區安全性監測數據，未發現新的安全性事件，未發生導致停藥或退出的不良事件（AE），未發生研究藥物相關的嚴重不良事件（SAE）。 此次產品白癜風適應症獲批，將為國內千萬白癜風患者帶來治療新希望，滿足市場迫切的臨床需求。同時，產品將進一步豐富德鎂醫藥在皮膚治療領域的產品矩陣，並有望與現有處於商業化階段的創新藥益路取（替瑞奇珠單抗注射液）、獨家藥喜遼妥（多磺酸粘多糖乳膏），以及系列在研創新藥和皮膚學級護膚品等在專家網絡與市場資源等方面產生協同，提升德鎂醫藥在皮膚健康領域的地位。此外，康哲藥業於中國開展的磷酸蘆可替尼乳膏治療輕中度特應性皮炎患者的III期臨床試驗，已取得陽性結果。截至目前，康哲藥業正在中國積極推進磷酸蘆可替尼乳膏治療特應性皮炎的新藥上市申請，如若獲批上市，將為中國廣大特應性皮炎患者群體提供新的治療選擇。關於白癜風適應症白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。據估算，中國約有1030萬人患有白癜風，其中約820萬人患有非節段型白癜風[4]。現有療法，如外用糖皮質激素（TCS）及外用鈣調神經磷酸酶抑制劑（TCIs）存在臨床缺陷，長期用藥有不良反應或療效有限。磷酸蘆可替尼乳膏NDA獲批，成功填補了白癜風靶向藥物治療的空白，具有重大標誌性意義。關於磷酸蘆可替尼乳膏的更多資訊磷酸蘆可替尼乳膏（Opzelura®）是Incyte開發的選擇性JAK1/JAK2抑制劑蘆可替尼製成的一種創新型乳膏，在美國獲批用於局部治療成人及12歲及以上患者的非節段型白癜風，及2歲及以上非免疫力功能低下患者的輕度至中度特應性皮炎的局部短期和非連續性慢性治療。在歐洲，磷酸蘆可替尼乳膏被批准用於治療成年及12歲及以上青少年面部受累的非節段型白癜風。康哲藥業於2022年12月2日，通過德鎂醫藥的附屬公司與Incyte就磷酸蘆可替尼乳膏訂立合作和許可協議（「許可協議」），獲得在中國大陸、香港特別行政區、澳門特別行政區、台灣地區及東南亞十一國（「區域」）研發、注冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。德鎂醫藥的附屬公司已將磷酸蘆可替尼乳膏除中國大陸外的其他區域的相關權利再許可予康哲藥業（不包括德鎂醫藥及其附屬公司）。Incyte擁有磷酸蘆可替尼乳膏全球開發和商業化權利，在美國及歐洲以Opzelura®的名稱銷售。Opzelura®和Opzelura®標識是Incyte的註冊商標。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.FDA批准資訊可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2.EMA批准資訊可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3.相關臨床研究資訊可在Opzelura®官網查詢，網址：https://www.opzelura.com/opzelura-prescribing-information4.數據來自灼識諮詢報告康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和-醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TSUKUBA, Japan, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Modern industry relies heavily on catalysts, which are substances that speed up chemical reactions. They’re vital in everything from manufacturing household chemicals to generating clean energy or recycling waste. However, designing new catalysts is challenging because their performance is affected by many interacting factors.A new tool uses a catalyst gene profiling, where catalysts are represented as symbolic sequences, making it easier for scientists to interpret data and design catalysts without a need for programming skills.A new tool developed by researchers at Hokkaido University, published in Science and Technology of Advanced Materials: Methods, will simplify the process by providing researchers with a way to easily view and explore data about catalysts, enabling them to identify patterns and relationships in catalyst datasets without needing advanced programming or computational skills.The tool takes advantage of an approach known as catalyst gene profiling, where catalysts are represented as symbolic sequences. This makes it easier for scientists to interpret the data and apply sequence-based analysis methods to design and improve catalysts. The tool itself is a web-based graphical interface that offers an intuitive and interactive way to investigate these catalyst profiles.“The system enables researchers to explore complex catalyst datasets, identify global trends, and recognize local features—all without requiring advanced programming skills,” explains Professor Keisuke Takahashi, who led the study. “By visualizing both the relationships among catalysts and the underlying gene-based features, the platform makes catalyst design more interpretable, accessible, and efficient, bridging the gap between data-driven analysis and practical experimental insight.”Users can view catalysts clustered together based on how similar their features are or how similar their sequences are. The tool also includes a heat map that offers insights into how the catalyst gene sequences are calculated. The different visualizations can be viewed side by side and are synchronized so they all update simultaneously when a user zooms in or selects a group of catalysts.The team plans to extend the tool to work with other material science datasets so it can be used more broadly in the field. They’re also working to include a predictive component. Integrating modeling and editing strategies would mean researchers could use the tool not only to explore existing catalysts but also to investigate new ideas for high-performance materials. In addition, they want to improve the tool’s collaborative features so that several researchers can work together to explore and annotate datasets, enabling a community-oriented, data-driven approach to material design and discovery.“Our goal is to make advanced materials research more intuitive, approachable, and impactful,” says Takahashi.Further informationKeisuke TakahashiHokkaido University keisuke.takahashi@sci.hokudai.ac.jpPaper: https://doi.org/10.1080/27660400.2025.2600689 About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-MDr Kazuya SaitoSTAM Methods Publishing Director SAITO.Kazuya@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Feb 1, 2026 - (ACN Newswire via SeaPRwire.com) - TCG.Zone (The Collectors Grid), a key player in the global collectibles infrastructure and ecosystem, has officially unveiled its strategic shift toward prioritizing investments in high-value, rare collectible assets. This strategic realignment underscores the company’s commitment to tapping into the long-term value and cultural significance of elite collectibles, with the recent participation in a high-profile international auction serving as a pivotal first step in this new direction.Recently, the world's only Pokémon card graded PSA 10 - Pikachu Illustrator - once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment.Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory.The Legendary Status of the World's Only PSA 10According to publicly available information, the world's only PSA 10 "Pikachu Illustrator" card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting.The Industry Significance of Goldin AuctionsAlthough Logan Paul's acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card's contemporary circulation and visibility. As one of the world's most influential high-end collectibles auction platforms, Goldin's auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market.Netflix Documentary Captures a Cultural MomentAmid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference.Global Participation and TCG.Zone's InvolvementThe discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand.Continuing to Follow the Card's Future TrajectoryIn post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world's only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value.The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting.About TCGThe Collectors Grid is an on-chain infrastructure designed to formalize collectibles as a structured asset class. By integrating provenance, ownership, pricing, and settlement at the protocol level, it addresses long-standing inefficiencies in the global collectibles market. The platform enables institutional-grade transparency while preserving the unique characteristics of collectible assets. Positioned as a settlement layer rather than a marketplace, The Collectors Grid provides the foundational rails for liquidity, valuation, and long-term capital participation in cards, IP, and high-value collectibles.Social LinksTwitter: https://x.com/tcgzoneofficialInstagram: https://www.instagram.com/tcgzoneofficial/Telegram: https://t.me/tcgzoneofficialMedia ContactBrand : The Collectors Grid (tcg.zone)Contact: AnnieWebsite: https://www.tcg.zone Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MOSCOW, Jan 31, 2026 - (ACN Newswire via SeaPRwire.com) - Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead.Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise "The Third Rome" and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations.Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades."By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society," Oreshkin said. "Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives."1. A New Global Economic Paradigm: Globalisation 2.0A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements."Globalisation hasn't ended; it has changed," Oreshkin said. "Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world."China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and "connector countries" like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy.2. Platformisation and Institutional AutomationThe second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond."Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms," Oreshkin said. "Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts."3. Transformation of the Global Financial SystemIt was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance."The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system," he said.4. Demographic Shifts and ChallengesThe fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services."Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%," Oreshkin explained. "Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other."5. Human Capital Development in the Technological EraThe final megatrend focuses on human capital in a rapidly changing technological environment.Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities."AI is both a challenge and an opportunity," Oreshkin said. "It allows personalized learning paths and supports teachers.Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era."Global PerspectiveThroughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands."The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future," Oreshkin concluded.Open Dialogue on AirThis year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna.First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually.Social LinksTelegram: https://t.me/gowithrussiaVK: https://vk.com/gowithrussiaOK: https://ok.ru/gowithrussiaDZen: https://dzen.ru/gowithrussiaContact for the mediaBrand: Russia National CentreContact: Media teamEmail: Pressa@russia.ru Website: https://russia.ruEssay Submission: https://dialog.russia.ru/en/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Jan 30, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone's real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's position in the field of skin health.Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3. The clinical studies information can be found on the Opzelura® official website, as follows:https://www.opzelura.com/opzelura-prescribing-information4. China Insights Consultancy’s industrial reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – As China’s first batch of Level 3 (L3) conditionally autonomous driving vehicles receives official market access, advanced smart driving is poised for its inaugural year of commercial explosion. At this pivotal juncture, Cheche Group Inc. (CCG) ("Cheche" or the "Company"), a leading global InsurTech platform, announced the signing of a strategic cooperation agreement with Volkswagen (Anhui) Digital Sales and Services Co., Ltd. (hereinafter "DSSO") and Beijing Cardif Airstar Property & Casualty Insurance Co., Ltd. (hereinafter "Cardif Airstar Insurance").This tripartite collaboration is more than just a deep dive into high-quality growth for New Energy Vehicle (NEV) insurance; it represents a core transition from "digitization" to "intelligence." The partnership establishes three strategic directions for synergy. First, it focuses on the transformation of product formats by leveraging Cheche’s SaaS platform to co-create an integrated "Insurance + Value-Added Services" package, enabling the efficient, one-stop fulfillment of high-value services. Second, it upgrades pricing capabilities by deeply integrating compliant driving data with dynamic vehicle information, utilizing AI-driven risk profiling to achieve differentiated precision pricing while addressing the complex challenge of liability determination in human-machine co-driving scenarios. Finally, it expands the ecosystem dimension by embedding insurance services throughout the vehicle sales and after-sales process, extending the business from a single policy to a full-lifecycle service ecosystem that encompasses renewal management and mobility protection.01. Smart Driving Insurance: Securing "Pricing Authority" in the L3 Mass Production EraTraditional auto insurance has long struggled with "human-machine co-driving" scenarios due to a lack of real-time dynamic data for liability determination and precise risk identification. Having served leading automakers such as Tesla, Li Auto, and Xiaomi, Cheche provides VW Anhui Digital with an embedded SaaS system centered on data attribution and dynamic pricing.Through this SaaS infrastructure, vehicle driving data is seamlessly synchronized with BNP Paribas Star’s actuarial models. This AI-driven joint risk profiling not only resolves the technical difficulties of liability judgment in smart driving scenarios but also delivers a "low-premium rewards for safe drivers," serving as a vital solution to the profitability challenges currently facing the NEV insurance industry.02. Ecosystem Breakthrough: Leveraging the "Xiaomi + Volkswagen DSSO" New Quality Productive ForcesInvestors are closely watching the cross-sector dynamics underpinning this collaboration. Cardif Airstar Insurance was co-founded by Xiaomi Group, Volkswagen Financial Services, and Cardif Airstar Insurance, combining the strengths of an internet giant, a global financial powerhouse, and a leading smart automaker.As the hub connecting these forces with Volkswagen’s Hefei Intelligent Electric Vehicle Center, Cheche is penetrating the world’s top smart driving supply chains. This is not merely system integration; it marks Cheche’s evolution into a digital operator within the "Vehicle-Battery-Charging-Insurance" integrated landscape. Amid policy tailwinds such as "New Quality Productive Forces," Cheche’s closed-loop ecosystem is becoming a definitive growth pole for insurance and tech capital.03. Scenario Transformation: From Transactional Policies to Full-Lifecycle OperationsIn 2026, as the automotive market shifts from a competition over hardware parameters to a competition over user experience, Cheche is helping DSSO deeply couple insurance services with the car-buying and after-sales journey. The integrated service package transforms insurance from a low-frequency tool into a high-frequency touchpoint for user engagement.Christian Koenig, After-sales Director of DSSO, noted that Cheche’s technical foundation allowed the partnership to advance rapidly from a high starting point. This "plug-and-play" empowerment capability, proven by mainstream automakers, has become a technical moat for Cheche in the capital markets.04. Conclusion: The Final Piece of the Trillion-Dollar Blue OceanThe year 2026 marks the point where NEV insurance evolves from scale expansion to intelligent upgrades. Cheche will continue to advance its AI pricing engine, driving the leap from digital to intelligent services.According to data released by the Ministry of Public Security on January 26, China’s NEV ownership reached 43.97 million units by the end of 2025, accounting for 12.01% of the total vehicle population—a growth rate exceeding 40% year-over-year. In this environment, those who define the insurance standards for the smart driving era will control the entry point to future mobility. With its high barriers to entry via OEM partnerships and forward-looking AI layouts, Cheche is racing toward becoming a leader in the trillion-dollar NEV insurance market. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – 27 January 2026, Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) announced its continued support for elite athletes from The Education University of Hong Kong (“EdUHK”) for the fourth consecutive year. The Presentation Ceremony for the Nissin Foods Scholarship for Elite Athletes 2025/2026 was held to honour seven outstanding athletes who not only demonstrate excellence in their respective sports but also aspire to become future educators. The scholarship will cover their full tuition fees throughout their entire study period, enabling them to pursue their academic and athletic goals without financial concerns.Established in 2022 by the Nissin Foods (Hong Kong) Charity Fund, the scholarship is designed to encourage elite athletes enrolled in the Bachelor of Health Education (Honours), Bachelor of Science (Honours) in Sports Science and Coaching, or the Postgraduate Diploma in Education programme at EdUHK. The initiative aims to support their dual career development, empowering them to become qualified health educators while continuing to strive for excellence in their athletic performance.The seven awardees for the 2025/2026 academic year include new and renewing recipients. The four new awardees are: Mr. MOK Pak Fan (triathlon), Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), and Miss YAN Nuo (shuttlecock). In addition to welcoming new scholars, the Charity Fund also made the scholarship renewable to support the elite athletes throughout their study period. The three recipients of the renewed scholarship are: Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).Mr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund, said, “Having been deeply rooted in Hong Kong for over four decades, Nissin Foods is steadfast in its mission to give back to the community. This scholarship is a direct reflection of our founder Mr. Momofuku Ando’s philosophy that ‘Eating and sports are the two axles of health.’ By supporting these talented athletes at EdUHK for the fourth year, we are not just providing financial support, we are investing in future leaders who will champion health and wellness in our society. We are proud to empower them on their dual career path, confident that they will inspire the next generation as both accomplished athletes and dedicated educators.”Expressing his profound gratitude for the long-standing partnership, Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK, said, “EdUHK is dedicated to promoting sustainable dual-career pathways for high-performance athletes. The generous Nissin Foods Scholarship for Elite Athletes allows us to support both active and retired athletes in advancing their educational pursuits, while also recognising their exceptional sporting accomplishments. I would like to extend my heartfelt congratulations to all the scholarship recipients, who demonstrated great passion, determination, and a sense of mission, and sincerely thank the Nissin Foods (Hong Kong) Charity Fund, and Mr Ando for the tremendous support and confidence in health education and the development of elite athletes.”Accomplished volleyball player Miss HO Kin Yiu, recipient of the scholarship from the Postgraduate Diploma in Education, majoring in Chinese and Physical Education, shared her heartfelt appreciation to the Charity Fund, “The support of the scholarship empowers us, as elite athlete-students, to chase our aspirations and make a meaningful influence on society. We are confident that we can help create a brighter future through the spirit of sports and education.”PhotoMr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund (middle right), and Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK (middle left), attended the Presentation Ceremony for Nissin Foods Scholarship for Elite Athletes 2025/2026 on 27 January 2026. Five scholarship recipients attended the ceremony, including four new awardees for the 2025/2026 academic year, namely: (from left to right) Mr. MOK Pak Fan, Mr. WONG Pak Yiu, Miss HO Kin Yiu, and Miss YAN Nuo, as well as the renewed awardee - Mr. CHOI Kwan Lok. Awardees of the Nissin Foods Scholarship for Elite Athletes 2025/2026 are achieving great success in their individual disciplines. From top left: Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), Mr. MOK Pak Fan (triathlon), Miss YAN Nuo (shuttlecock), Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).About Nissin Foods (Hong Kong) Charity FundThe Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) was set up in September 2020 by way of a trust deed by Nissin Foods Company Limited (Stock code: 1475). The objectives of the Charity Fund are: a) to advance education, teaching, learning, arts, science and academic research; b) to make provision for people in need; and c) to carry out works of a charitable nature that are beneficial to the Hong Kong community. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月30日 - (亞太商訊 via SeaPRwire.com) - 2026年1月27日，日清食品（香港）慈善基金（「慈善基金」）宣布連續第四年支持香港教育大學（「教大」）精英運動員，並舉行2025/2026 學年日清食品精英運動員獎學金頒獎典禮，以表彰在各自運動領域中表現卓越、並立志成為未來教育工作者的七位精英運動員。該獎學金將支付整個修業期的全額學費，確保他們能夠專注追求學業及運動目標，無須擔心財務負擔。該獎學金於2022年由日清食品（香港）慈善基金設立，以鼓勵於教大修讀健康教育（榮譽）學士課程、運動科學及教練（榮譽）理學士及學位教師教育文憑課程的精英運動員。此舉措旨在支持他們的雙軌事業發展，賦予他們能力成為合資格的健康教育工作者，同時在運動表現上繼續追求卓越。2025/2026 學年的七名得獎者包括新晉及續期獎學金的精英運動員。四名新得獎的精英運動員分別是：鐵人三項代表莫柏勛先生和黃栢堯先生、排球代表何健瑤小姐以及香港足毽隊代表閻諾小姐。除了新的獎學金得主，慈善基金亦將該獎學金設為可續期形式，為精英運動員提供整個學習期間的資助支持。獲得續期獎學金的三名精英運動員包括：前香港單車隊代表蔡鈞樂先生、賽艇代表陳柏匡先生及香港單車隊代表劉睿哲先生。日清食品（香港）慈善基金主席安藤清隆先生表示：「日清食品在香港扎根逾 40 年，我們堅定不移地履行回饋社會的使命。獎學金直接體現了我們的創辦人安藤百福先生『飲食和運動是健康的兩大軸心』的理念。透過連續第四年支持教大的傑出運動員，我們不僅提供經濟資助，更是在投資未來的領袖，他們將在我們的社會中倡導健康與福祉。我們很自豪能在他們的雙軌發展道路上賦予他們力量，並深信他們將以傑出運動員和敬業教育工作者的雙重身份，啟發下一代。」香港教育大學副校長（研究與發展）陳智軒教授對長期的合作夥伴關係表達深切感謝。他表示：「教大致力推動精英運動員發展可持續的雙軌事業路徑。日清食品精英運動員獎學金的慷慨支持令我們能夠讓現役及退役運動員繼續進修，同時認可了他們卓越的運動成就。我衷心祝賀所有獎學金得主，他們展現了極大的熱情、決心和使命感，並誠摯感謝日清食品（香港）慈善基金及安藤先生對健康教育和精英運動員發展的巨大支持及信心。」主修中文及體育的學位教師教育深造文憑獎學金得獎人及傑出排球運動員何健瑤小姐對慈善基金表達衷心謝意。她說：「獎學金的支持賦予我們精英運動員學生力量，去追逐我們的抱負，並為社會帶來有意義的影響。我們深信，我們能透過體育和教育的精神，創造更美好的未來。」圖片說明日清食品（香港）慈善基金主席安藤清隆先生（中間右）及香港教育大學副校長（研究與發展）陳智軒教授（中間左）於2026年1月27日出席2025/2026學年日清食品精英運動員獎學金頒獎典禮。五名獎學金得主參與典禮，包括四名新得獎的精英運動員學生（從左至右）莫柏勛先生、黃栢堯先生、何健瑤小姐及閻諾小姐，以及獲得續期獎學金的精英運動員學生蔡鈞樂先生。 2025/2026年度日清食品精英運動員獎學金得獎人在各自領域均表現出色。左上起：鐵人三項代表黃栢堯先生、排球代表何健瑤小姐、鐵人三項代表莫柏勛先生、香港足毽隊代表閻諾小姐、前香港單車隊代表蔡鈞樂先生、賽艇代表陳柏匡先生及香港單車隊代表劉睿哲先生。關於日清食品（香港）慈善基金日清食品（香港）慈善基金（「慈善基金」）於2020年 9月由日清食品有限公司（股份編號： 1475）以信託契約的形式成立。慈善基金致力推動教育、教學、學習、藝術、科學和學術研究、援助有需要人士及進行惠及香港社區的慈善工作。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月30日 - (亚太商讯 via SeaPRwire.com) - 日清食品（香港）慈善基金（「慈善基金」）宣布连续第四年支持香港教育大学（「教大」）精英运动员，并举行2025/2026 学年日清食品精英运动员奖学金颁奖典礼，以表彰在各自运动领域中表现卓越、并立志成为未来教育工作者的七位精英运动员。该奖学金将支付整个修业期的全额学费，确保他们能够专注追求学业及运动目标，无须担心财务负担。该奖学金于2022年由日清食品（香港）慈善基金设立，以鼓励于教大修读健康教育（荣誉）学士课程、运动科学及教练（荣誉）理学士及学位教师教育文凭课程的精英运动员。此举措旨在支持他们的双轨事业发展，赋予他们能力成为合资格的健康教育工作者，同时在运动表现上继续追求卓越。2025/2026 学年的七名得奖者包括新晋及续期奖学金的精英运动员。四名新得奖的精英运动员分别是：铁人三项代表莫柏勋先生和黄柏尧先生、排球代表何健瑶小姐以及香港足毽队代表阎诺小姐。除了新的奖学金得主，慈善基金亦将该奖学金设为可续期形式，为精英运动员提供整个学习期间的资助支持。获得续期奖学金的三名精英运动员包括：前香港单车队代表蔡钧乐先生、赛艇代表陈柏匡先生及香港单车队代表刘睿哲先生。日清食品（香港）慈善基金主席安藤清隆先生表示：「日清食品在香港扎根逾 40 年，我们坚定不移地履行回馈社会的使命。奖学金直接体现了我们的创办人安藤百福先生『饮食和运动是健康的两大轴心』的理念。透过连续第四年支持教大的杰出运动员，我们不仅提供经济资助，更是在投资未来的领袖，他们将在我们的社会中倡导健康与福祉。我们很自豪能在他们的双轨发展道路上赋予他们力量，并深信他们将以杰出运动员和敬业教育工作者的双重身份，启发下一代。」香港教育大学副校长（研究与发展）陈智轩教授对长期的合作伙伴关系表达深切感谢。他表示：「教大致力推动精英运动员发展可持续的双轨事业路径。日清食品精英运动员奖学金的慷慨支持令我们能够让现役及退役运动员继续进修，同时认可了他们卓越的运动成就。我衷心祝贺所有奖学金得主，他们展现了极大的热情、决心和使命感，并诚挚感谢日清食品（香港）慈善基金及安藤先生对健康教育和精英运动员发展的巨大支持及信心。」主修中文及体育的学位教师教育深造文凭奖学金得奖人及杰出排球运动员何健瑶小姐对慈善基金表达衷心谢意。她说：「奖学金的支持赋予我们精英运动员学生力量，去追逐我们的抱负，并为社会带来有意义的影响。我们深信，我们能透过体育和教育的精神，创造更美好的未来。」图片说明日清食品（香港）慈善基金主席安藤清隆先生（中间右）及香港教育大学副校长（研究与发展）陈智轩教授（中间左）于2026年1月27日出席2025/2026学年日清食品精英运动员奖学金颁奖典礼。五名奖学金得主参与典礼，包括四名新得奖的精英运动员学生（从左至右）莫柏勋先生、黄柏尧先生、何健瑶小姐及阎诺小姐，以及获得续期奖学金的精英运动员学生蔡钧乐先生。 2025/2026年度日清食品精英运动员奖学金得奖人在各自领域均表现出色。左上起：铁人三项代表黄柏尧先生、排球代表何健瑶小姐、铁人三项代表莫柏勋先生、香港足毽队代表阎诺小姐、前香港单车队代表蔡钧乐先生、赛艇代表陈柏匡先生及香港单车队代表刘睿哲先生。关于日清食品（香港）慈善基金日清食品（香港）慈善基金（「慈善基金」）于2020年 9月由日清食品有限公司（股份编号： 1475）以信托契约的形式成立。慈善基金致力推动教育、教学、学习、艺术、科学和学术研究、援助有需要人士及进行惠及香港社区的慈善工作。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月30日 - (亞太商訊 via SeaPRwire.com) - 1月30日，由香港大公文匯傳媒集團聯合香港中國企業協會、香港中國金融協會、香港中資證券業協會、香港公司治理公會主辦的第十五屆香港國際金融論壇暨中國證券「金紫荊獎」頒獎典禮在香港JW萬豪酒店舉行。中國電信股份有限公司（以下簡稱「中國電信」）憑藉卓越的經營表現，榮獲2025中國證券「金紫荊獎」「最具投資價值上市公司」與「卓越投資者關係管理上市公司」兩項大獎，這不僅是對公司投資價值與經營成效的肯定，更是對其不斷優化投資者關係管理工作、始終堅持高水平公司治理、持續提升信息披露質量與透明度、不斷構建科學完善的合規管理體系的認可。當前，新一輪科技革命和產業變革迅猛發展，人工智能正在深刻改變人類生產生活方式，成為推動經濟社會高質量發展的重要驅動力。隨著人工智能邁入規模應用的元年，大模型、智能體等人工智能應用在各領域加快普及、深度融合，助力傳統產業改造升級，開闢戰略性新興產業和未來產業發展新賽道，行業發展迎來廣闊空間。2025年上半年，中國電信完整、準確、全面貫徹新發展理念，堅定履行建設網絡強國、科技強國、數字中國和維護網信安全的責任，準確把握科技創新和產業發展趨勢，全面擁抱人工智能，推動企業戰略由「雲改數轉」向「雲改數轉智惠」升級，持續推進企業高質量發展。擁抱人工智能 探索智慧方案公司堅持以客戶為中心，緊跟數字消費新場景新趨勢，不斷豐富高質量產品服務供給， 以戰新業務為引領，扎實推進基礎業務和產數業務雙輪驅動、創新發展。持續推動基礎業務創新發展，加快連接提速升級，加速推進移動網絡向5G-A升級、家庭寬帶向千兆和FTTR升級，並不斷加大直連衛星業務、量子密話密信規模拓展。中國電信加快終端融智升級，率先發佈自研星小辰智能體，賦能終端升級，加快推進AI手機、AI中屏、AI攝像頭等終端規模發展，積極探索AI眼鏡、AI機器人等前沿領域。加快應用融智升級，不斷通過AI升級推動通信助理、雲盤、雲計算機、視頻彩鈴等業務智能煥新，並推出AI文創等新智能應用；進一步升級「美好家」產品體系，讓用戶暢享安全家、健康家、娛樂家、低碳家、智能家等多場景智慧家庭應用。公司加快平台融智升級，在持續推動數字鄉村、智慧社區、智慧家庭等平台融通的基礎上，進一步以AI視聯、AI物聯為抓手，加快推進平台智能升級，推動基礎業務規模與價值穩步提升。持續推進產業數字化業務創新發展，加快打造業內領先的行業大模型場景應用，累計推出80餘個行業大模型、30余個行業智能體，上線星辰MaaS平台和星辰行業Agent平台，提供一體化的智能雲服務，在政務、應急、工業、能源化工、住建等領域形成成熟商業模式。加快行業數字平台能力升級，圍繞智慧城市、社會民生、應急安全等重點領域推出一攬子行業解決方案，120餘個數字平台持續賦能各類行業客戶。加快打造「5G+AI+雲+應用」的5G定制網一體化產品體系，推出5G工控智能體等產品，助力客戶提升生產效率、降低安全風險、提高生產質量，廣泛應用於礦山、製造、電力等領域。加快打造「5個1」創新標準ICT能力體系，提供滿足中小企業客戶辦公及生產等通用場景的一體化解決方案，首創集全光組網、通用算力、智算於一體的算網一體化服務器，新型融合網關累計發展近50萬套。矢志創新發展 加快建設科技領軍企業中國電信持續推進高水平科技自立自強，加快關鍵核心技術攻關，強化高質量科技供給，連續兩年入選中央企業科技創新優秀企業榜單。從底層基礎設施到上層應用全方位推進面向人工智能的技術創新，自研天翼雲服務器操作系統通過國家安全可靠測評；突破算力融合調度、訓練推理加速等關鍵技術，創新提出Triless架構，實現資源、框架與工具三重解耦，推動跨服務商、跨地區、跨架構的多元算力互聯互通，蟬聯中國算力互聯調度市場第一，穩居中國智算雲服務市場領導者象限；持續升級星辰多模態大模型，打造擬真人自然對話能力，創新提出全模態、可解釋性鑒偽能力，獲得ICCV 2025、IJCAI 2025 AI鑒偽賽道冠軍；創新構建智傳網(AI Flow)技術體系，攻關生成式智能傳輸、家族式同源模型、基於連接和交互的智能湧現三大關鍵技術，推動通信、網絡與人工智能的深度融合；自主實現高性能隱私計算協議簇，突破百億級海量數據聯合計算性能瓶頸，獲得「吳文俊人工智能科技進步獎」；攻關高質量數據集構建與治理關鍵技術，「網絡大模型」和「城市治理」數據集入選「中央企業人工智能行業高質量數據集優秀建設成果」；發佈全球首個融合QKD和PQC的分布式密碼系統；行業首創雲網端協同的抗DDoS技術，推出國內首個開源大模型基礎安全護欄，防護能力達到業界領先水平。公司不斷深化基礎理論研究，基於擴散模型的生成式編碼圖像新框架研究獲得ICME 2025唯一「最佳論文獎」；高水平建設科技創新基礎設施，雲網融合大科創裝置入選中央企業中試驗證平台；持續打造高質量標準專利，5G專利在第二十五屆中國專利獎評選中榮獲專利銀獎。中國電信董事長兼首席執行官柯瑞文表示，未來，公司將全面實施雲改數轉智惠戰略，強化創新引領的基礎業務和產數業務雙輪驅動融合發展；深入推進「人工智能+」行動，讓智能紅利更好惠及千行百業和千家萬戶；加快推動數字信息基礎設施智能化演進升級，讓智能服務更加觸手可及；進一步全面深化改革開放，著力激發企業高質量發展的活力動力；不斷增強核心功能、提升核心競爭力，加快建設世界一流企業，堅定履行建設網絡強國、科技強國、數字中國和維護網信安全的責任，在推進中國式現代化中走在前、勇擔當、作表率。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月30日 - (亞太商訊 via SeaPRwire.com) - 1月30日，由香港大公文匯傳媒集團聯合香港中國企業協會、香港中國金融協會、香港中資證券業協會、香港公司治理公會主辦的第十五屆香港國際金融論壇暨中國證券「金紫荊獎」頒獎典禮在香港JW萬豪酒店舉行。中國核能電力股份有限公司（以下簡稱「中國核電」或「公司」，股票代碼：601985）憑藉卓越的經營治理和規範的董事會治理結構，奪得2025中國證券「金紫荊獎」「卓越上市公司董事會秘書」與「卓越投資者關係管理上市公司」兩項大獎。中國核電由中國核工業集團有限公司作為控股股東，聯合中國長江三峽集團有限公司、中國遠洋海運集團有限公司和航天投資控股有限公司共同出資設立。中國核電投資控股秦山核電、江蘇核電、福清核電、海南核電、三門核電、漳州能源、遼寧核電等七大核電在運、在建核電基地，控股中核匯能負責風電、光伏等可再生能源開發，受託管理建設霞浦核電基地。探索創新驅動 推動公司高質量發展今年是中國核電上市十周年。十年間，公司實現跨越式發展：總資產從2632億元（人民幣，下同）增至6597億元，營業收入從262億元提升至772億元，市值突破1900億元，較「十三五」末上漲約150%。站在新的發展起點，公司推出「集約化、標準化、數智化」新「三化」戰略，精准契合高質量發展需求。經過多年積累，中國核電已在技術、安全、產業規模、經濟性、自主創新及多場景應用等方面形成顯著優勢。在創新驅動方面，公司始終堅持將科技創新視為推動公司高質量發展的關鍵核心。基於科技創新價值鏈，圍繞科技創新的三大核心業務——科研項目、人才、科技成果，系統性構建適合中國核電的「三位一體」科技創新體系。公司以實現高質量發展和高水平安全為目標，加強創新發展頂層謀劃，充分發揮業主在產業鏈中的創新引領作用，將卓越績效模式全面導入科技創新和科研管理全過程，堅持做有組織的科研和有價值的科研，推動產業鏈創新，深化科技體制改革，加大核心技術攻關力度，促進產學研融合與成果轉化，加強人才培育，完善創新平台建設，加快佈局戰略性新興產業和未來產業，精准對標世界一流企業，高水平建設先進技術研發基地，開啟全面推進核科技自立自強新征程。在市場開發優勢方面，中國核電緊扣"8+3+2"戰略佈局，持續完善產業管理體系，強化資源配置，以核為主、以能為輔，積極拓展科技革命和產業變革形勢下的新業態領域與新商業模式。參股中國聚變能源有限公司，聚焦鈣鈦礦太陽能電池、堆產同位素及數智產業等重點領域，加快培育形成新質生產力，致力於打造新的經濟增長引擎。公司積極響應國家"一帶一路"倡議，搶抓海外能源市場機遇，設立國際市場部，統籌管理公司國際市場開發和技術服務業務。與國內外多家知名機構和企業集團達成戰略合作協議，深化國際產能合作，全方位打造「八方核護」 技術服務品牌矩陣影響力，製作中英俄多國語言技術服務產品手冊，展示中國核電技術服務優勢，為實現高質量"走出去"戰略目標奠定堅實基礎。深化科技與新能源產業融合，堅持以模式創新賦能產業升級，順利推進氫基能源項目，探索佈局「智算中心+新能源」電算一體化項目，積極推動熔鹽超二發電項目，持續升級推廣「天光地熱」模式，以新業態新模式的前瞻佈局塑造產業發展新優勢。持續穩定分紅 重視股東回報公司高度重視落實股東回報，穩定投資者分紅預期。今年上半年，公司積極開展股份回購工作，維護資本市場穩定。四月，在關稅貿易戰的影響下，資本市場遭遇重創，為維護公司全體股東利益，增強投資者信心，穩定及提升公司價值，公司董事長盧鐵忠提議公司通過集中競價交易方式回購部分公司股份，回購資金總額不低於人民幣3億元（含）且不超過人民幣 5 億元（含）。截至到 2025 年 7 月 31 日，公司累計回購股份數量為 11,113,000 股，佔公司目前總股本的比例為 0.05%，已支付的總金額為 104,936,335.80 元（不含傭金等交易費用）。2025 年 7 月 18 日，公司以扣除公司回購專用證券賬戶中股份數 7,865,500 股後的公司股本20,560,136,574 股為基數實施 2024 年年度利潤分配，每股派發現金紅利 0.16 元（含稅），共計派發現金紅利 3,289,621,851.84 元。公司在《中國核能電力股份有限公司章程》中承諾，每年以現金方式分配的利潤不少於當年實現的可分配利潤的 30%。但是公司自上市以來，每年以現金分紅分配的比例不低於當年實現的可分配利潤的 35%，且為切實增強投資者回報，公司 2024 年年度現金分紅比例達到歷史最高值 41.90%，共計派發現金紅利 36.67 億元。截至 2025 年 6 月 30 日，公司累計現金分紅 11 次，現金分紅金額超 242 億元。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月30日 - (亞太商訊 via SeaPRwire.com) - 1月30日，由香港大公文匯傳媒集團聯合香港中國企業協會、香港中國金融協會、香港中資證券業協會、香港公司治理公會主辦的第十五屆香港國際金融論壇暨中國證券「金紫荊獎」頒獎典禮在香港JW萬豪酒店舉行。華能國際電力股份有限公司（以下簡稱「華能國際」或「公司」）憑藉卓越的戰略規劃和穩健的經營發展，榮獲2025中國證券「金紫荊」獎「卓越上市公司」大獎，公司董事長王葵入選「金紫荊」獎「2025年度經濟人物」，這些榮譽不僅是對華能國際過去一年取得成績的肯定，更是對華能國際始終堅持高水平公司治理、持續提升信息披露質量與透明度、不斷構建科學完善的合規管理體系的高度認可。華能國際是中國最大的上市發電公司之一，自成立以來秉持「三色」公司企業使命，以加快創建國際一流上市發電公司為引領，持續優化能源供給結構，不斷加強安全風險管控，深耕精細化管理，提升資本運營水平，推動用能成本降低，為用戶提供清潔低碳、安全高效的能源電力綜合服務。截至2025年第三季度，公司可控發電裝機容量超過1.5億千瓦，低碳清潔能源裝機占比超過40%。引領行業技術革新 彰顯卓越領軍實力多年來，華能國際銳意進取，規模逐年擴大，競爭實力不斷增強，在設備規模、轉型發展、創新驅動、區域佈局、治理結構、市場信譽、資本運作、海外發展、隊伍建設及股東支持等多方面具有諸多發展優勢；在電力技術進步、電廠建設和管理方式等方面創造了多項國內行業第一和里程碑工程，推動了中國電力事業的跨越式發展和電站設備製造業的技術進步，促進了中國發電企業技術水平和管理水平的提高。華能國際在中國首次引進了60萬千瓦「超臨界」發電機組；投運了國內首台單機容量100萬千瓦及首台數字化百萬千瓦超超臨界燃煤機組，建成了世界上首台使用海水脫硫百萬千瓦機組以及國內最高參數的66萬千瓦高效超超臨界燃煤機組，建成了國內首座超超臨界二次再熱燃煤發電機組，開發了火電廠煙氣協同治理技術，並在環保改造和新建工程中廣泛應用，自主研發的「國家首台（套）」重大技術裝備全國產安全智能型DCS/DEH一體化分散控制系統在百萬千瓦超超臨界高效二次再熱機組投運，並得到推廣應用；大力推動東線沿海地區海上風電基地建設，打造形成海上風電集群化開發優勢；建成了中巴經濟走廊首個重大能源項目，創造了中國海外電力建設工程安全、質量和進度最好記錄；公司技術經濟指標、全員勞動生產率在國內電力行業保持先進水平。2025年，華能國際加強行業政策研究和市場分析，動態優化煤炭採購策略，強化各項成本控制，經營業績再上新台階。加速綠色轉型佈局 創新研發成果顯著華能國際堅持以高質量發展為主題，緊緊圍繞年度目標任務，積極進取，砥礪攻堅，安全形勢保持平穩，經營效益同比提升，轉型發展步伐加快，改革創新釋放活力，總體呈現了高開穩走的良好態勢，為經濟社會發展作出了積極貢獻。華能國際不斷優化電源結構和區域佈局，鞏固常規能源領先地位，加快發展新能源，提高產業協同效果，拓展配售服務領域，實現運營水平、質量效益和企業活力全面提升。公司持續推進綠色低碳轉型，風電和光伏裝機容量持續增長，促進新能源電量同比增長。2025年，公司新增新能源裝機容量接近7000兆瓦，低碳清潔能源裝機占比超過40%，實現同比大幅提升。華能國際聚焦服務國家戰略，增加對戰略新興產業、未來產業的研發投入，前瞻性佈局儲熱、綠電制氫、地熱供暖、虛擬電廠等多個領域，持續推進高質量科技成果轉化。臨沂電廠COAP近零排放技術成果獲中國電機工程學會「國際領先」技術鑒定，湖北虛擬電廠首次參與電力現貨市場調電試運行獲得成功，「黃海一號」入選世界經濟論壇全球可再生能源案例，世界首台650℃高效超超臨界燃煤發電機組開工建設，多項研發專利在日內瓦國際發明展中斬獲金獎。立足新起點，邁向新征程。華能國際將聚焦「雙碳」目標，以高質量發展為主線，繼續深化企業改革，強化創新驅動，拓展綠色版圖，以更加昂揚的姿態參與並推動能源電力行業的變革，致力於為股東、為社會、為國家創造更大價值。第十五屆中國證券「金紫荊」獎評選活動由香港大公文匯傳媒集團主辦，本屆評選及頒獎典禮以「記錄產業變革，賦能金融創新」為使命，搭建起兩地資本市場溝通的橋樑。本次活動彙聚了內地及香港財經界官員、國內外券商高管、投資機構、上市公司等各界精英，共同探討產業發展、金融發展的新趨勢、新機遇。香港大公文匯傳媒集團立足香港，致力於中國內地、香港地區與國際資本市場的信息互通和相互交流，被譽為香港與內地、中國與世界的「超級聯絡人」。2011年起，大公報聯合兩地政府機構、權威機構、在香港推出「金紫荊」香港國際金融周系列活動，其中包括全球路演大會、香港國際金融論壇及中國證券「金紫荊獎」等。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com